← All trials
NCT03944876
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2019
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- University of LondonCollaborator
- University of Duisburg-EssenCollaborator
- Norwegian University of Science and TechnologyCollaborator
- Norwegian University of Science and TechnologyStudy director
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaCollaborator
- Catholic University of ValenciaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.